Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.62
(
0.42%
)
Bitcoin
80,944.65
(
-0.14%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 137112

Friday, 02/17/2012 4:26:45 PM

Friday, February 17, 2012 4:26:45 PM

Post# of 257566
The Copaxone language in Teva’s 20-F filing is somewhat different from the bluster you hear from executives on investor presentations. The 20-F says:

http://www.sec.gov/Archives/edgar/data/818686/000119312512067417/d300203d20f.htm

…our patents on Copaxone have been challenged, and we may face generic competition prior to 2014, when the U.S. Orange Book patents covering Copaxone would otherwise expire.

On investor CC’s, Teva’s executives say that there’s no chance in hell this can occur.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today